Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells

Toxicology

Volumn 285, Issue 1-2, 2011, Pages 18-24

  Rigalli, Juan Pablo ^a   Ruiz, María Laura ^a   Perdomo, Virginia Gabriela ^a   Villanueva, Silvina Stella Maris ^a   Mottino, Aldo Domingo ^a   Catania, Viviana Alicia ^a  

^a UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

Cytotoxicity; HepG2 cells; P glycoprotein; Pregnane X receptor; SiRNA; Spironolactone

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; KETOCONAZOLE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR; RHODAMINE 123; SMALL INTERFERING RNA; SPIRONOLACTONE; VERAPAMIL;

ARTICLE; CELL STRAIN HEPG2; CELL VIABILITY; CYTOTOXICITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ALDOSTERONE ANTAGONISTS; BLOTTING, WESTERN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG INTERACTIONS; HEP G2 CELLS; HUMANS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; RECEPTORS, STEROID; RHODAMINE 123; RNA, MESSENGER; SPIRONOLACTONE; UP-REGULATION; VERAPAMIL;

EID: 79956192123     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2011.03.015     Document Type: Article

References (42)

1. Alqawi O., Bates S., Georges E. Arginine 482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem. J. 2004, 382:711-716.
2. Ambudkar S.V., Kimchi-Sarfaty C., Sauna Z.E., Gottesman M.M. P-glycoprotein: from genomics to mechanism. Oncogene 2003, 22:7468-7485.
3. Catania V.A., Sánchez Pozzi E.J., Luquita M.G., Ruiz M.L., Villanueva S.S.M., Jones B., Mottino A.D. Co-regulation of expression of phase II metabolizing enzymes and multidrug resistance-associated protein. Ann. Hepatol. 2004, 3:11-17.
4. Deeley R., Westlake C., Cole S. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86:849-899.
5. Di Masi A., De Marinis E., Ascenzi P., Marino M. Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol. Aspects Med. 2009, 30:297-343.
6. Geick A., Eichelbaum M., Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 2001, 276:14581-14587.
7. Germain P., Staels B., Dacquet C., Spedding M., Laudet V. Overview of nomenclature of nuclear receptors. Pharmacol. Rev. 2006, 58:685-704.
8. Ghanem C.I., Gómez P.C., Arana M.C., Perassolo M., Delli Carpini G., Luquita M.G., Veggi L.M., Catania V.A., Bengochea L.A., Mottino A.D. Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin. J. Pharm. Exp. Ther. 2006, 318:1146-1152.
9. Greiner B., Eichelbaum M., Fritz P., Kreichgauer H.P., von Richter O., Zundler J. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104:147-153.
10. Guo G.L., Choudhuri S., Klaassen C.D. Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J. Pharmacol. Exp. Ther. 2002, 300:206-212.
11. Guo G.L., Moffit J.S., Nicol C.J., Ward J.M., Aleksunes L.A., Slitt A.L., Kliewer S.A., Manautou J.E., González F.J. Enhanced acetaminophen toxicity by activation of the pregnane X receptor. Toxicol. Sci. 2004, 82:374-380.
12. Huang H., Wang H., Sinz M., Zoeckler M., Staudinger J., Redinbo M.R., Teotico D.G., Locker J., Kalpana G.V., Mani S. Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 2007, 26:258-268.
13. Igarashi M., Yogiashi Y., Mihara M., Takada I., Kitagawa H., Kato S. Vitamin K induces osteoblast differentiation through pregnane x receptor-mediated transcriptional control of the Msx2 gene. Mol. Cell. Biol. 2007, 27:7947-7954.
14. Jones S.A., Moore L.B., Shenk J.L., Wisely G.B., Hamilton G.A., McKee D.D., Tomkinson N.C., LeCluyse E.L., Lambert M.H., Willson T.M., Kliewer S.A., Moore J.T. The pregnane X receptor: a promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 2000, 14:27-39.
15. Jungsuwadee P., Cole M.P., Sultana R., Joshi G., Tangpong J., Butterfield D.A., St Clair D.K., Vore M. Increase in Mrp1 expression and 4-hydroxy-2-nonenal adduction in heart tissue of Adriamycin-treated C57BL/6 mice. Mol. Cancer Ther. 2006, 5:2851-2860.
16. Karim A. Spironolactone: disposition, metabolism, pharmacodynamics, and bioavailability. Drug Metab. Rev. 1978, 8:151-188.
17. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev. 2010, 62:1-96.
18. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23:687-702.
19. Köhle C., Bock K.W. Coordinate regulation of human drug-metabolizing enzymes, and conjugate transporters by the Ah receptor, pregnane X receptor and constitutive androstane receptor. Biochem. Pharmacol. 2009, 77:689-699.
20. Kota B.P., Tran V.H., Allen J., Bebawy M., Roufogalis B.D. Characterization of PXR mediated P-glycoprotein regulation in intestinal LS174T cells. Pharmacol. Res. 2010, 62:426-431.
21. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T., Kliewer S.A. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 expression and cause drug interactions. J. Clin. Invest. 1998, 102:1016-1023.
22. Marguerite V., Beri-Dexheimer M., Ortiou S., Guéant J.L., Merten M. Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cell Physiol. Biochem. 2007, 20:967-976.
23. Masuyama H., Suwaki N., Tateichi Y., Nakatsukasa H., Segawa T., Hiramatsu Y. The pregnane X receptor regulates gene expression in a ligand- and promoter-selective fashion. Mol. Endocrinol. 2005, 19:1170-1180.
24. Miguet J.P., Vuitton D., Thebault-Lucas A., Joanne C., Dhumeaux D. Spironolactone and enzyme induction in patients with alcoholic cirrhosis. Gastroenterology 1980, 78:996-1000.
25. Naspinski C., Gu X., Zhou G.D., Mertens-Talcott S.U., Donnelly K.C., Tian Y. Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicol. Sci. 2008, 104:67-73.
26. Ochs H.R., Greenblatt D.J., Bodem G., Smith T.W. Spironolactone. Am. Heart J. 1978, 96:389-400.
27. Olinga P., Elferink M.G., Draaisma A.L., Merema M.T., Castell J.V., Pérez G., Groothuis G.M. Coordinated induction of drug transporters and phase I and II metabolism in human liver slices. Eur. J. Pharm. Sci. 2008, 33:380-389.
28. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001, 29:e45.
29. Robinson-Rechavi M., Escriva García H., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 2003, 116:585-586.
30. Ruiz M.L., Villanueva S.S., Luquita M.G., Sánchez Pozzi E.J., Crocenzi F.A., Pellegrino J.M., Ochoa J.E., Vore M., Mottino A.D., Catania V.A. Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance associated protein 2. Biochem. Pharmacol. 2005, 69:531-539.
31. Ruiz M.L., Villanueva S.S., Luquita M.G., Pellegrino J.M., Rigalli J.P., Arias A., Sánchez Pozzi E.J., Mottino A.D., Catania V.A. Induction of intestinal multidrug resistance-associated protein 2 (Mrp2) by spironolactone in rats. Eur. J. Pharmacol. 2009, 623:103-106.
32. Saradhi M., Sengupta A., Mukhopadhyay G., Tyagi R.K. Pregnane and xenobiotic receptor (PXR/SXR) resides predominantly in the nuclear compartment of the interphase cell and associates with the condensed chromosomes during mitosis. Biochim. Biophys. Acta 2005, 1746:85-94.
33. Schinkel A.H., Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003, 55:3-29.
34. Schuetz E.G., Beck W.T., Schuetz J.D. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol. 1996, 49:311-318.
35. Schuetz E.G., Brimer C., Schuetz J.D. Environmental xenobiotics and the antihormone cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the Cyp3A23 hormone response element. Mol. Pharmacol. 1998, 51:1113-1117.
36. Sedmak J.J., Grossberg S.E. A rapid, sensitive, and versatile assay for protein using Coomassie brilliant blue G250. Anal. Biochem. 1977, 79:544-552.
37. Sormunen R., Eskelinen S., Lehto V.P. Bile canaliculus formation in cultured HEPG2 cells. Lab. Invest. 1993, 68:652-662.
38. Verschraagen M., Koks C.H., Schellens J.H., Beijnen J.H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 1999, 40:301-306.
39. Wirth K.E., Frölich J.C., Hollifield J.W., Falker F.C., Sweetman B.S., Oates J.A. Metabolism of digitoxin in man and its modulation by spironolactone. Eur. J. Clin. Pharmacol. 1976, 9:345-354.
40. Xu C., Li C.Y., Kong A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28:249-268.
41. Zhang Y., Gupta A., Wang H., Zhou L., Vethanayagam R.R., Unadkat J.D., Mao Q. BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm. Res. 2005, 22:2023-2034.
42. Zhou S.F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008, 38:802-832.